Recent Security Class Actions

Kyverna Therapeutics Inc. Common Stock (NASDAQ: KYTX)

11 Days left to seek lead plaintiff status.

Company Name:Kyverna Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: KYTX
Class Period Start:02/08/2024
Class Period End (inclusive):12/09/2024
Filing Deadline:02/07/2025

On February 8, 2024, Kyverna conducted its IPO, offering 14.5 million shares of its common stock to the public at a price of $22 per share for anticipated proceeds of over $296 million. Kyverna granted the Underwriter Defendants a 30-day option to purchase up to an additional 2.175 million shares of its common stock at the Offering Price, less underwriting discounts and commissions.

The Complaint alleges that the registration statement and prospectus issued in connection with the Company’s IPO misstated and/or omitted facts concerning the results of the Company’s ongoing evaluation of KYV-101 in clinical trials. The Complaint further alleges that unbeknownst to investors, these representations were materially inaccurate, misleading, and/or incomplete because they did not disclose adverse data regarding one of Kyverna’s trials, which adverse data was known to the Company at the time of the IPO.

Kyverna Therapeutics Inc. Common Stock (NASDAQ: KYTX) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.